Our Story:
What is CV6?
CV6 Therapeutics is developing a new class of therapies designed to amplify the effectiveness of widely used treatments and restore anti-cancer activity when resistance emerges.
Its lead program, CV6-168, targets a fundamental biological mechanism linked to 5-FU activity and resistance. With early clinical data demonstrating strong tolerability and predictable pharmacology, CV6 aims to improve outcomes across multiple major cancers by enhancing therapies already relied upon worldwide.
Meet Bob Ladner
“I like to fish where no one else is fishing.”
That mindset has defined Dr. Robert Ladner’s career. While much of the industry moved toward entirely new therapies, he stayed the course, following the data and focusing on how to make treatments already relied on by millions of patients more effective, including a cancer drug first developed over 60 years ago.
Even the name CV6 reflects that thinking, inspired by a vessel built for resilience and impact at scale. In this conversation, he explains why.
Latest News
View all
Test Press Release
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...
CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...